Nisoldipine
- Generic Name
- Nisoldipine
- Brand Names
- Sular
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24N2O6
- CAS Number
- 63675-72-9
- Unique Ingredient Identifier
- 4I8HAB65SZ
- Background
Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Nisoldipine may be used in alone or in combination with other agents in the management of hypertension.
- Indication
For the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
- Associated Conditions
- Hypertension
Bioequivalence Study of Nisoldipine Extended-Release Tablets, 30 mg
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-09-28
- Last Posted Date
- 2009-09-28
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 78
- Registration Number
- NCT00985660
- Locations
- 🇺🇸
PRACS Institute Ltd., Fargo, North Dakota, United States
Single-Dose Fed Bioequivalence Study of Nisoldipine Extended-Release Tablets (40 mg; Mylan) and Sular® Extended-Release Tablets (40 mg; First Horizon) in Healthy Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2009-09-18
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 83
- Registration Number
- NCT00979537
- Locations
- 🇺🇸
Pracs Institute, Ltd, Fargo, North Dakota, United States
Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy
- Conditions
- Diabetic Nephropathy
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2006-04-06
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 52
- Registration Number
- NCT00311870
- Locations
- 🇩🇰
Steno Diabetes Center, Gentofte, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.